The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
How sensitive are epidermal growth factor receptor tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring epidermal growth factor receptor gene–sensitive mutations?
A. Hata
No relevant relationships to disclose
N. Katakami
No relevant relationships to disclose
K. Kunimasa
No relevant relationships to disclose
H. Yoshioka
No relevant relationships to disclose
S. Fujita
No relevant relationships to disclose
R. Kaji
No relevant relationships to disclose
Y. Imai
No relevant relationships to disclose
K. Tomii
No relevant relationships to disclose
M. Iwasaku
No relevant relationships to disclose
A. Nishiyama
No relevant relationships to disclose
T. Ishida
No relevant relationships to disclose